Responsiveness and minimally important difference of SF-6D and EQ-5D utility scores for the treatment of pelvic organ prolapse

被引:22
|
作者
Harvie, Heidi S. [1 ]
Honeycutt, Amanda A. [2 ]
Neuwahl, Simon J. [2 ]
Barber, Matthew D. [3 ]
Richter, Holly E. [4 ]
Visco, Anthony G. [5 ]
Sung, Vivian W. [6 ]
Shepherd, Jonathan P. [7 ]
Rogers, Rebecca G. [8 ,9 ]
Jakus-Waldman, Sharon [10 ]
Mazloomdoost, Donna [11 ]
机构
[1] Univ Penn, Dept Obstet & Gynecol, Philadelphia, PA 19104 USA
[2] RTI, Clin Res Network Coordinat, Res Triangle Pk, NC USA
[3] Cleveland, Dept Obstet & Gynecol, Cleveland, OH USA
[4] Univ Alabama Birmingham, Dept Obstet & Gynecol, Birmingham, AL 35294 USA
[5] Duke Univ, Dept Obstet & Gynecol, Durham, NC USA
[6] Brown, Dept Obstet & Gynecol, Providence, RI USA
[7] Univ Pittsburgh, Dept Obstet & Gynecol, Pittsburgh, PA USA
[8] Univ New Mexico, Dept Obstet & Gynecol, Albuquerque, NM 87131 USA
[9] Univ Texas Austin, Dell Med Sch, Dept Womens Hlth, Austin, TX 78712 USA
[10] Kaiser Downey, Dept Obstet & Gynecol, Downey, CA USA
[11] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Bethesda, MD USA
基金
美国国家卫生研究院;
关键词
EuroQol; health-related quality of life; minimal important difference; pelvic floor disorders; pelvic organ prolapse; Short Form 6D; utility score; QUALITY-OF-LIFE; VAGINAL PROLAPSE; HEALTH; TERMINOLOGY; STATE;
D O I
10.1016/j.ajog.2018.11.1094
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
BACKGROUND: Utility preference scores are standardized, generic, health-related quality of life (HRQOL) measures that quantify disease severity and burden and summarize morbidity on a scale from 0 (death) to 1 (optimal health). Utility scores are widely used to measure HRQOL and in cost-effectiveness research. OBJECTIVE: To determine the responsiveness, validity properties, and minimal important difference (MID) of utility scores, as measured by the Short Form 6D (SF-6D) and EuroQol (EQ-5D), in women undergoing surgery for pelvic organ prolapse (POP). MATERIALS AND METHODS: This study combined data from 4 large, U.S., multicenter surgical trials enrolling 1321 women with pelvic organ prolapse. We collected condition-specific quality of life data using the Pelvic Floor Distress Inventory (PFDI) and Pelvic Floor Impact Questionnaire (PFIQ). A subset of women completed the SF6D; women in 2 trials also completed the EQ5D. Mean utility scores were compared from baseline to 12 months after surgery. Responsiveness was assessed using effect size (ES) and standardized response mean (SRM). Validity properties were assessed by (1) comparing changes in utility scores at 12 months between surgical successes and failures as defined in each study, and (2) correlating changes in utility scores with changes in the PFDI and PFIQ. MID was estimated using both anchor-based (SF-36 general health global rating scale "somewhat better" vs "no change") and distribution-based methods. RESULTS: The mean SF-6D score improved 0.050, from 0.705 +/- 0.126 at baseline to 0.761 +/- 0.131 at 12 months (P < .01). The mean EQ-5D score improved 0.060, from 0.810 +/- 0.15 at baseline to 0.868 +/- 0.15 at 12 months (P<.01). The ES (0.13-0.61) and SRM(0.13-0.57) were in the small-to-moderate range, demonstrating the responsiveness of the SF-6D and EQ-5D similar to other conditions. SF-6D and EQ-5D scores improved more for prolapse reconstructive surgical successes than for failures. The SF-6D and EQ-5D scores correlated with each other (r = 0.41; n = 645) and with condition-specific instruments. Correlations with the PFDI and PFIQ and their prolapse subscales were in the low to moderate range (r = 0.09-0.38), similar to other studies. Using the anchor-based method, theMID was 0.026 for SF-6D and 0.025 for EQ-5D, within the range of MIDs reported in other populations and for other conditions. These findings were supported by distribution-based estimates. CONCLUSION: The SF-6D and EQ-5D have good validity properties and are responsive, preference-based, utility and general HRQOL measures for women undergoing surgical treatment for prolapse. The MIDs for SF-6D and EQ-5D are similar and within the range found for other medical conditions.
引用
收藏
页码:265.e1 / 265.e11
页数:11
相关论文
共 50 条
  • [41] Population Norms for the EQ-5D-5L, PROPr and SF-6D in Hungary
    Nikl, Anna
    Janssen, Mathieu F.
    Jenei, Balazs
    Brodszky, Valentin
    Rencz, Fanni
    PHARMACOECONOMICS, 2024, 42 (05) : 583 - 603
  • [42] How should we measure the impact of chronic pain? Limitations of utility measurement using the EQ-5D and SF-6D
    Schofield, Deborah J.
    PAIN, 2014, 155 (10) : 1918 - 1919
  • [43] What is the relationship between the minimally important difference and health state utility values? The case of the SF-6D
    Stephen J Walters
    John E Brazier
    Health and Quality of Life Outcomes, 1 (1)
  • [44] Comparison of preference-based utilities of the 15D, EQ-5D and SF-6D in patients with HIV/AIDS
    Stavem, K
    Froland, SS
    Hellum, KB
    QUALITY OF LIFE RESEARCH, 2005, 14 (04) : 971 - 980
  • [45] Mapping Catquest Scores onto EQ-5D Utility Values in Patients With Cataract Disease
    Yousefi, Mahmood
    Sheikhrobat, Yousef Behzadi
    Najafi, Safa
    Ghaffari, Shahram
    Ghaderi, Hossein
    Memarzadeh, Seyed Ezatollah
    Mahboub-Ahari, Alireza
    Barouni, Mohsen
    Biglu, Mohammad-Hossein
    IRANIAN RED CRESCENT MEDICAL JOURNAL, 2017, 19 (05)
  • [46] Mapping the Chinese Version of the EORTC QLQ-BR53 Onto the EQ-5D-5L and SF-6D Utility Scores
    Liu, Tong
    Li, Shunping
    Wang, Min
    Sun, Qiang
    Chen, Gang
    PATIENT-PATIENT CENTERED OUTCOMES RESEARCH, 2020, 13 (05) : 537 - 555
  • [47] Comparison of the EQ-5D 3L and the SF-6D (SF-36) contemporaneous utility scores in patients with chronic kidney disease in Sri Lanka: a cross-sectional survey
    Kularatna, Sanjeewa
    Senanayake, Sameera
    Gunawardena, Nalika
    Graves, Nicholas
    BMJ OPEN, 2019, 9 (02):
  • [48] Comparison of preference-based utilities of the 15D, EQ-5D and SF-6D in patients with HIV/AIDS
    Knut Stavem
    Stig S. Frøland
    Kjell B. Hellum
    Quality of Life Research, 2005, 14 : 971 - 980
  • [49] Comparing the performance of the EQ-5D and SF-6D when measuring the benefits of alleviating knee pain
    Garry R Barton
    Tracey H Sach
    Anthony J Avery
    Michael Doherty
    Claire Jenkinson
    Kenneth R Muir
    Cost Effectiveness and Resource Allocation, 7 (1)
  • [50] Comparison of the EQ-5D-3L and the SF-6D (SF-12) contemporaneous utility scores in patients with cardiovascular disease
    Kularatna, Sanjeewa
    Byrnes, Joshua
    Chan, Yih Kai
    Ski, Chantal F.
    Carrington, Melinda
    Thompson, David
    Stewart, Simon
    Scuffham, Paul A.
    QUALITY OF LIFE RESEARCH, 2017, 26 (12) : 3399 - 3408